An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis.
Primary focal hyperhidrosis (HH) is a chronic disorder of excessive sweating. A single-center, open-label study was performed to determine the efficacy and safety of 15% aluminum chloride (AC) in 2% salicylic acid gel base (SAGB) Hydrosal in adults with moderate-to-severe primary axillary HH. Thirty subjects were given 15% AC in 2% SAGB to apply to their bilateral axillae nightly for the first week, then twice-weekly application as tolerated. The primary objective was change in mean Hyperhidrosis Disease Severity Score (HDSS) score from baseline to week 4. Participants who achieved an HDSS score < 2 were designated as "responders." Mean change in HDSS from baseline to week 4 was 1.32 (p = 0.0001). At week 4, 21 of 29 (72%) were responders, and at week 12, 18 of 25 (72%) were responders. Based on these results, 15% AC in 2% SAGB may be an effective, high-strength AC topical therapy for treatment of patients with moderate-to-severe axillary HH.
Flanagan
Katherine H
KH
Department of Dermatology, Saint Louis University School of Medicine, St. Louis, MO, USA.
Glaser
Dee Anna
DA
D000287:Administration, Topical; D000328:Adult; D000077410:Aluminum Chloride; D017607:Aluminum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001252:Astringents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001365:Axilla; D002712:Chlorides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D020156:Salicylic Acid; D013546:Sweating / Q000187:drug effects; D016896:Treatment Outcome
D017607:Aluminum Compounds; D001252:Astringents; D002712:Chlorides; D005782:Gels; D000077410:Aluminum Chloride; D020156:Salicylic Acid